메뉴 건너뛰기
Journal of Clinical Oncology
Volumn 26, Issue 12, 2008, Pages 2062-2063
Reporting of subset analysis: Where do we draw the line?
Author keywords

[No Author keywords available]
Indexed keywords

BEVACIZUMAB; CARBOPLATIN; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;
EID: 42949118295     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.16.2354     Document Type: Letter
Times cited : (1)
References (6)
  • 1
    • 37849052774 scopus 로고    scopus 로고
    • Outcomes for elderly, advanced-stage non-small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: Analysis of Eastern Cooperative Oncology Group trial 4599
    • Ramalingam SS, Dahlberg SE, Langer CJ, et al: Outcomes for elderly, advanced-stage non-small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: Analysis of Eastern Cooperative Oncology Group trial 4599. J Clin Oncol 26:60-65, 2008
    • (2008) J Clin Oncol , vol.26 , pp. 60-65
    • Ramalingam, S.S.1    Dahlberg, S.E.2    Langer, C.J.3
  • 2
    • 33845490014 scopus 로고    scopus 로고
    • Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
    • Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550, 2006
    • (2006) N Engl J Med , vol.355 , pp. 2542-2550
    • Sandler, A.1    Gray, R.2    Perry, M.C.3
  • 3
    • 33750967313 scopus 로고    scopus 로고
    • Effect of gender on outcome in two randomized phase III trials of paclitaxel poliglumex (PPX) in chemonaïve pts with advanced NSCLC and poor performance status (PS2)
    • suppl; abstr 7039, 373s
    • Ross H, Bonomi P, Langer C, et al: Effect of gender on outcome in two randomized phase III trials of paclitaxel poliglumex (PPX) in chemonaïve pts with advanced NSCLC and poor performance status (PS2). J Clin Oncol 25:373s, 2006 (suppl; abstr 7039)
    • (2006) J Clin Oncol , vol.25
    • Ross, H.1    Bonomi, P.2    Langer, C.3
  • 4
    • 33745886796 scopus 로고    scopus 로고
    • PIONEER: A phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapy-naive women with advanced-stage non-small-cell lung cancer and performance status of 2
    • Albain KS, Belani CP, Bonomi P, et al: PIONEER: A phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapy-naive women with advanced-stage non-small-cell lung cancer and performance status of 2. Clin Lung Cancer 7:417-419, 2006
    • (2006) Clin Lung Cancer , vol.7 , pp. 417-419
    • Albain, K.S.1    Belani, C.P.2    Bonomi, P.3
  • 5
    • 20644457721 scopus 로고    scopus 로고
    • FOLFOX for stage II colon cancer? A commentary on the recent FDA approval of oxaliplatin for adjuvant therapy of stage III colon cancer
    • Grothey A, Sargent DJ: FOLFOX for stage II colon cancer? A commentary on the recent FDA approval of oxaliplatin for adjuvant therapy of stage III colon cancer J Clin Oncol 23:3311-3313, 2005
    • (2005) J Clin Oncol , vol.23 , pp. 3311-3313
    • Grothey, A.1    Sargent, D.J.2
  • 6
    • 2542615200 scopus 로고    scopus 로고
    • Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
    • André T, Boni C, Mounedji-Boudiaf L, et al: Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343-2351, 2004
    • (2004) N Engl J Med , vol.350 , pp. 2343-2351
    • André, T.1    Boni, C.2    Mounedji-Boudiaf, L.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.